← Library
Prescription-only medicine. This page is educational information only. Do not use without a licensed prescriber.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Pramlintide

FDA approved · Rx

Amylin analog

Also known as: Symlin, Symlinpen, Triproamylin, pramlintida, TRIPRO-AMYLIN, AC0137, AC137, AC-137, AC-0137, pramlintidum

Evidence score
95/ 100
Strong evidence

Strong, human-grade evidence

  • Regulatory standing. FDA-approved prescription medicine
  • Human trials. Backed by controlled human studies
  • Registered human trials. 64 registered studies on ClinicalTrials.gov, most advanced Phase 4
  • 2 cited sources. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Pramlintide is a synthetic version of amylin, a hormone released by the pancreas alongside insulin. It is thought to act by slowing stomach emptying, reducing the post-meal rise in glucagon, and promoting a feeling of fullness, which together help limit blood sugar spikes after meals.

What the evidence shows

Automatic summaryHuman trials

Pramlintide is FDA approved for use with mealtime insulin in adults with type 1 or type 2 diabetes who have not reached blood sugar goals with insulin alone, supported by 64 registered human trials reaching Phase 4. Uses outside this approved indication are not established.

Key facts

Molecular formula
C171H267N51O53S2
Molecular weight
3949 g/mol
FDA approval
Confirmed on openFDA

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

64registered studies
Phase 4most advanced phase
44completed (sample)
1recruiting (sample)

A Trial to Investigate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BioChaperone® Pramlintide Insulin in Patients With Type 1 Diabetes Mellitus

Phase 1CompletedNCT03512236

Effect of Basal-Bolus Closed-Loop Co-Administration of Insulin and Pramlintide on Improving the Glycemic Control in Type 1 Diabetes

Phase 2CompletedNCT02814123

A Trial to Assess a Co-formulation of an Insulin Analog and Pramlintide in Subjects With Type 1 Diabetes Mellitus

Phase 1CompletedNCT03916640

Amylin and CGRP Head to Head Provocation in Migraine Without Aura Patients

CompletedNCT03598075

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

485papers referencing Pramlintide

Insulin-associated weight gain in diabetes--causes, effects and coping strategies.

Diabetes Obes Metab2007

Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies.

Proc Natl Acad Sci U S A2008

Amylin: Pharmacology, Physiology, and Clinical Potential.

Pharmacol Rev2015

Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25.

Br J Pharmacol2018

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.